Patient needs in China drive everything we do. By providing much-needed treatment options for neuro-immune disorders, BioShin will be at the forefront of the country’s healthcare revolution.

BioShin’s name comes from a Chinese phrase meaning “unique” and “at the forefront.” The name highlights the company's vision of building a new model of biopharmaceutical company.

BioShin Limited, is a privately-held biopharmaceutical company with offices in Shanghai and Beijing. As a start-up, we have launched in China with a full neuroinnovation portfolio of late-stage clinical assets for neuro-immune diseases, including rare diseases, that it in-licensed from the U.S, making us uniquely positioned to address significant unmet needs for patients in China and the Asia-Pacific region as a young company. Our strategy is to develop and commercialize these assets, as well as in-license assets from other companies to bring innovation to the region.

The neuroinnovation portfolio includes the US FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine and other CGRP-mediated disorders; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; and myeloperoxidase inhibition for multiple system atrophy and amyotrophic lateral sclerosis.

Biohaven is a majority shareholder in BioShin.

BioShin closed a $60M series A round in September 2020 with leading life-science investors, it is set to deliver its current pipeline of assets and future opportunities to the Asia-Pacific market.

The financing was led by OrbiMed, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company), and Suvretta Capital Management, LLC.

Deep roots in academic and industry settings:

We are a team of drug developers and commercial professionals with strong track records of delivery and accountability. We have worked on a wide array of approved medicines, in disciplines ranging from basic science through clinical development, regulatory approval and global marketing.